Palisade Bio Reports Second Quarter 2023 Financial Results
– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline – Strong financial position with cash to fund operations through 2024 Carlsbad, CA, Aug. 11, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today summarized […]
Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
– Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery Carlsbad, CA, Aug. 09, 2023 — Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported that the Company’s U.S. Phase 2 PROFILE […]
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the completion of patient enrollment in its dose optimization study of LB1148. “Achieving our enrollment target in this study is an important […]
Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Live webcast fireside chat on Thursday, June 22nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 — Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio will present at the Healthcare Virtual Conference Part II, presented […]
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
Carlsbad, CA, June 01, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley has been named Chief Executive Officer (CEO), effective today. Mr. Finley has been serving as interim CEO since October 2022. “Since assuming the […]
Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose optimization study with 25% enrollment complete Carlsbad, CA, May 24, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provided […]
Palisade Bio Reports First Quarter 2023 Financial Results
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the first quarter 2023 and provided a corporate update. “We are looking […]
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be completed in Q3 2023 Carlsbad, CA, May 11, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal […]
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
Carlsbad, CA, April 06, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 2,942,358 titled, “Compositions for the Treatment of Autodigestion.” This key patent covers the composition of LB1148, […]
Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148
Enrollment triggers milestone payment Carlsbad, CA and Shanghai, China, April 05, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that its development partner Newsoara Biopharma Co. Ltd, has enrolled the first patient in its ongoing Phase 3 clinical […]